

October 28, 2016



***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

### **1. BMS Plans To Evolve Operating Model, Including Manufacturing**

As part of its third-quarter earnings release, Bristol-Myers Squibb announced what it termed "an evolution of its operating model" in the near and long term. Without providing specifics, the company said the model will emphasize a more focused investment in commercial opportunities against key brands and markets, a competitive and more agile R&D organization, streamlined operations, and realigned manufacturing capabilities that broaden biologics capabilities to reflect its current and future portfolio. [Read More](#)

### **2. Allergan Names New Chairman**

Allergan has appointed Brenton L. Saunders as chairman of the Allergan's Board of Directors, replacing Paul Bisaro, who has served as executive chairman since July 1, 2014. Bisaro will remain a member of the Allergan Board of Directors. In addition to the role of chairman, Saunders will retain his current role as CEO and president. [Read More](#)

### **3. Novartis Reports \$500 Million in 3Q Procurement Savings**

As part of its third-quarter earnings release, Novartis reported gross savings of approximately \$600 million in productivity initiatives in the third quarter, which included \$500 million in savings from procurement, achieved through leveraging scale. [Read More](#)

### **4. Allergan To Acquire Motus Therapeutics For \$200 Million....**

Allergan has exercised an option to acquire Motus Therapeutics, a biopharmaceutical company developing peptide therapeutics for treating gastrointestinal disorders and a wholly owned subsidiary of Rhythm Holding Company, for \$200 million. [Read More](#)

### **5. ...And Completes \$638 Million Acquisition of Vitae Pharmaceuticals**

Allergan has completed its tender offer to purchase all of the outstanding shares of Vitae Pharmaceuticals, a clinical-stage biopharmaceutical company for approximately \$639 million. [Read More](#)

### **6. Mylan Launches Generics of Daiichi Sanyko's Antihypertensive Drugs**

Mylan has launched in the US generic versions of two antihypertensive drugs by Daiichi Sankyo, Benicar and Benicar HCT, respectively olmesartan medoxomil tablets and olmesartan medoxomil and hydrochlorothiazide tablets, in various dosage forms. The drugs had respective US sales for the 12 months ending August 31, 2016 of \$1 billion and \$805 million. [Read More](#)

### **7. Teva, IBM Expand Partnership in Digital Health**

Teva Pharmaceutical Industries has expanded its existing global e-Health alliance with IBM with a new, three-year research pact to develop cognitive technologies to enable a systematic approach to the

emerging field of drug repurposing and for improving chronic disease management. Both projects will run on the IBM Watson Health Cloud. [Read More](#)

### 8. [Amgen Invests in Digital Health Company](#)

Amgen GmbH, a Zug, Switzerland-based affiliate of Amgen, has invested in eHealth Ventures, a Tel Aviv Israel-based digital-health incubator that is comprised of a consortium of organizations and investors active in the field of digital health. [Read More](#)

### 9. [Sterinova Launches as New Sterile Injectables Pharma Company](#)

Sterinova, headquartered in Saint-Hyacinthe, Quebec, Canada, has been launched as a new pharmaceutical company specializing in the development and manufacture of sterile ready-to-use injectable products. The new company was launched with an investment of approximately \$70 million from private and public investors. [Read More](#)

### 10. [Teva Receives FDA Warning Letter on Hungary Site](#)

Teva Pharmaceutical Industries reported that it received a FDA Warning Letter regarding a cGMP inspection of the company's Godollo, Budapest, Hungary manufacturing facility, which was conducted January 21, 2016 through January 29, 2016. The company said it has taken corrective actions to address the issues. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

### About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)